argenx SE
ARGX · Price history
Price at last available close
$891.76
−$78.90 (-8.13%) 1M
2026-10-28
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About argenx SE
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
argenx SE, a biotechnology company established in Amsterdam, the Netherlands, in 2008, is dedicated to developing innovative therapies primarily for autoimmune diseases. The company's operations span across key global markets, including the United States, Japan, Europe, the Middle East, Africa, and China. Its leading investigational therapy is efgartigimod, which is being developed to address a broad range of conditions.
How they make money
argenx is a global immunology company that generates revenue primarily through the commercialization of its proprietary antibody-based therapies. The company focuses on discovering and developing innovative treatments for severe autoimmune diseases, leveraging its proprietary immunology innovation pipeline to bring products to market globally.
Products & services
The company's primary commercial product is VYVGART (efgartigimod), a first-in-class FcRn blocker indicated for the treatment of various severe autoimmune diseases, available in multiple administration options including intravenous and subcutaneous forms.
Brands & revenue mix
The company's flagship FcRn blocker product line.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Calculated from reported segment revenue. Check the source period and revenue basis before comparing shares. Categories can overlap and may not add to 100%.
Customer concentration
The company's product sales are primarily driven by specialty pharmacies and distributors in the U.S., Europe, and Japan, with no single customer accounting for a majority of revenue as of the fiscal year ended December 31, 2025.
Suppliers, materials & equipment
- Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of its drug products and clinical trial materials; specific supplier names are not disclosed.Source
Business relationships & partnerships
- Zai Lab — A strategic collaboration for the development and commercialization of efgartigimod in Greater China.Source
Competitors
Strengths
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
63
Fair
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
84
Strong
Financial Strength
63
Business Quality / Moat
100
Management
100
Growth Quality
100
Risk / Durability
55
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
72
Fair
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
74/100
Building Historical Record
Model Score 74/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is mixed across its combined quality, valuation and risk inputs. Review the category scores to identify what is helping or hurting the result.
At today’s price, the WSS valuation framework currently reads as relatively attractive.
The model outlook is currently positive.
- •Valuation scores attractively
- •M&A headline · Aug 27, 2026
- •Debt / balance-sheet profile needs attention
Company-specific research
Questions worth answering for ARGX
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can ARGX maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •Is ARGX's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
- •How is ARGX likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •Is ARGX's valuation discount tied to a temporary concern or to a longer-term business risk?
Essential Investment Snapshot
Wall Street Score
63
Opportunity Score
72
Market Cap
$55.40B
P/E Ratio
26.6
EPS
$36.11
52-Week High
$1072.75
52-Week Low
$661.85
Beta
-0.02
Intrinsic Value
$1390.24
Analyst Target
$1167.50
Shares Outstanding
66.0M
Total Revenue
$7.54B
Total Debt
$47.0M
Dividend
No current dividend
Liquidation Value / Share
$127.47
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Neutral / mixed momentum
Normal movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for ARGX
Detected from reported data — verify before acting.M&A headline · Aug 27, 2026
argenx Completes Acquisition of Forte Biosciences, Inc. — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
GlobeNewsWireCommunity Sentiment
0 active · 0 total callsNo personal call yet on ARGX.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Proprietary immunology innovation pipeline.
- +Strong commercial execution of VYVGART.
- +Positive free cash flow may provide capacity to invest in growth.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Biotechnology industry.
- −Dependence on third-party manufacturers.
- −Regulatory approval and clinical trial success uncertainties.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
6 historical score records availablePrevious Score
61
Sep 8, 2026
Change
+1.4
points
Current Score
63
Oct 1, 2026
Category Changes
ARGX increased 1.4 points because Valuation improved by 6.1 points.
Positive Contributors
- + Valuation improved by 6.1 points
Projected Score
Projected Score
68
Projected Change
+5.2 points
Preliminary comparable-period financial changes suggest improvement of approximately 5.2 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
UndervaluedCurrent Price
$891.76
Model Intrinsic Value
$1390.24
Difference
−$498.48
-35.9% vs IV
Margin of Safety
35.9%
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Large reported revenue change: +89.6%
Revenue changed sharply from 2024 to 2025. This can reflect a real business change, acquisition, divestiture, discontinued operations, restatement, or reporting-basis change. Compare the underlying filing before treating it as normal growth or decline.
TTM may combine quarters from before and after the event, so its trend can also be distorted.
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.02B | $4.15B | $2.19B | $1.23B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $619.2M | $450.7M | $227.3M | $117.8M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $5.40B | $3.70B | $1.96B | $1.11B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $1.52B | $1.36B | $983.4M | $859.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $1.81B | $1.36B | $1.06B | $709.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $3.70B | $2.65B | $1.98B | $1.53B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | $1.89B | $1.31B | $105.2M | -$192.3M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | $1.70B | $1.05B | -$21.7M | -$425.0M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $5.0M | $4.1M | $2.2M | $904K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | $1.95B | $1.28B | $85.2M | -$304.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $64.1M | -$13.4M | -$747.9M | -$9.4M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | $1.89B | $1.29B | $833.0M | -$295.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $27.78 | $21.14 | $13.92 | $-5.16 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 62.19M | 61.30M | 59.86M | 57.17M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 64.41M | 66.03M | 65.18M | 57.17M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$2.82B
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
$13.02
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
+8.9%
Cash Change
+71.8%
Margin Change
+3.9 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Margins expanded
- Cash position grew
What Weakened
- Debt increased
Potential Score Impact
Positive indicators included revenue growth, EPS growth, cash levels, net income margin. Pressure indicators included debt levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 197.0%. EPS increased 104.4%. Cash increased 71.8%. Total debt increased 8.9%. Net income margin improved by 3.9 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
7
Smart Money
7
Number of Gurus
1
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
6 historical recordsHistorical Score Chart
3 of 6 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
argenx Meets Primary Endpoint in Phase II Celiac Disease Study
ARGX Stock Down on Stopping Late-Stage Autoimmune Disease Study
argenx: The Sjögren's Selloff Looks Overdone
argenx shares drop after trial of Vyvgart in Sjögren's disease is halted
Rumor Mill · ARGX
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial